Nantahala Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Nantahala Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.74M	Sell	486,684 -49,000	-9%	-$758K	0.29%	84
2026 Q1	$7.45M	Sell	535,684 -300,000	-36%	-$4.22M	0.27%	83
2025 Q4	$10.1M	Sell	835,684 -100,000	-11%	-$1.36M	0.33%	68
2025 Q3	$12.7M	Sell	935,684 -1,998,721	-68%	-$18.8M	0.44%	53
2025 Q2	$18.8M	Hold	2,934,405	–	–	0.74%	28
2025 Q1	$10.4M	Buy	2,934,405 +1,482,252	+102%	+$5.27M	0.41%	41
2024 Q4	$5.49M	Buy	1,452,153 +47,589	+3%	+$224K	0.24%	74
2024 Q3	$4.55M	Buy	+1,404,564	New	+$3.16M	0.23%	76
2024 Q1	–	Sell	-620,110	Closed	-$9.13M	–	125
2023 Q4	$9.13M	Buy	620,110 +212,905	+52%	+$3.26M	0.55%	41
2023 Q3	$7.46M	Buy	407,205 +242,705	+148%	+$5.13M	0.64%	38
2023 Q2	$3.55M	Buy	+164,500	New	+$4.44M	0.34%	60

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Nantahala Capital Management's AMLX Position: Q2 2026 in Review

Nantahala Capital Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 9.1% in Q2 2026, selling an estimated $758K and leaving 486,684 shares worth $8.74M. The position accounts for 0.29% of the portfolio, ranked #84.

Nantahala Capital Management first reported a position in AMLX in Q2 2023 and has held it in 11 quarters since. The position peaked at $18.8M in Q2 2025. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Nantahala Capital Management held 486,684 shares of Amylyx Pharmaceuticals worth $8.74M as of Q2 2026.
Nantahala Capital Management sold 49,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $758K.
Amylyx Pharmaceuticals made up 0.29% of Nantahala Capital Management's portfolio in Q2 2026, its #84 holding.
Nantahala Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
Nantahala Capital Management's Amylyx Pharmaceuticals position peaked at $18.8M in Q2 2025.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.